We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A leading COVID-19 vaccine candidate has shown promise as being safe and effective in humans and produced an immune response against the coronavirus, according to preliminary data from a phase 1 trial of 108 healthy adults in China. Read More
Enrollment for a large, global trial of chloroquine and hydroxychloroquine for the prevention of COVID-19 is getting under way in the United Kingdom. Read More
AstraZeneca has nabbed an HHS contract worth up to $1.2 billion to speed development and production of the University of Oxford’s promising COVID-19 vaccine candidate. The deal also would lock in the distribution of 300 million doses of the vaccine for the U.S. Read More
Covis Pharma has begun a phase 3 trial of its approved asthma drug Alvesco (ciclesonide) in non-hospitalized COVID-19 patients ages 12 years and older. Read More
Participants given the lower dose of 25 mcg had levels of antibodies equivalent to those seen in convalescent plasma from COVID-19 survivors. Read More